Pretty interesting article here which puts into context the...

Pretty interesting article here which puts into context the strategic importance for Merck or BMS to license or acquire a drug like Cavatak should it produce more positive data in combination studies. With their drugs being "on par" obtaining an advantage equals big bucks when you're talking about the potential annual markets for these drugs.

http://www.fiercepharma.com/story/m...val-data-stepped-battle-bms-opdivo/2015-12-21